journal
MENU ▼
Read by QxMD icon Read
search

Seminars in Hematology

journal
https://www.readbyqxmd.com/read/27788764/haploidentical-cord-transplantation-the-best-of-both-worlds
#1
REVIEW
Koen van Besien, Richard Childs
Haploidentical (haplo)-cord transplantation combines infusion of an umbilical cord blood (UCB) unit with CD34-selected cells usually from human leukocyte antigen (HLA) mismatched donors. Initial rapid count recovery from the haplo-hematopoietic progenitors, is gradually replaced by durable engraftment from UCB progenitors. UCB grafts used for haplo-cord are smaller, but better matched than those required for single or double UCB stem cell transplant (SCT). More than 200 patients with hematological malignancies have been transplanted...
October 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27788763/haploidentical-transplants-using-ex-vivo-t-cell-depletion
#2
REVIEW
Massimo F Martelli, Franco Aversa
Allogeneic hematopoietic stem cell transplantation (HSCT) is the best post-remission therapy for patients with acute leukemia (AL) at high risk of relapse. Advantages of having a family member as donor include: no undue delay in obtaining the graft; choice of best donor with regards to natural killer (NK) alloreactivity and cytomegalovirus (CMV) status from a panel of candidate family members; easy access to post-transplant cellular therapies like donor lymphocyte infusions and opportunity for a second graft from the original donor, or another family member in case of graft failure...
October 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27788762/selecting-the-best-haploidentical-donor
#3
REVIEW
Shannon R McCurdy, Ephraim J Fuchs
The substantial evidence of the safety of human leukocyte antigen (HLA)-haploidentical (haplo) blood or marrow transplantation (BMT) has led to its increasing utilization. When prioritizing HLA-matched grafts, patients frequently have few or no donors from whom to choose. However, a given patient may have multiple suitable haplo donors. Therefore factors other than HLA-match become critical for selecting the best donor. We recommend a donor selection algorithm based on the donor-specific antibodies, ABO match, donor age, donor sex, and cytomegalovirus (CMV) serostatus match...
October 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27788761/umbilical-cord-blood-cells-from-unrelated-donor-as-an-alternative-source-of-hematopoietic-stem-cells-for-transplantation-in-children-and-adults
#4
REVIEW
Vanderson Rocha
Umbilical cord blood (CB) is an alternative source of hematopoietic stem cells (HSC) for patients requiring allogeneic HSC transplantation but lacking a suitable human leukocyte antigen (HLA)-matched donor. Using CB has many advantages, including lower HLA-matching requirements, increased donor availability, and low rates of graft-versus-host disease. Furthermore, with over 630,000 cryopreserved volunteer CB units currently stored in international CB banks worldwide, CB is rapidly available for those patients requiring urgent transplantation...
October 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27788760/mismatched-unrelated-donor-transplantation
#5
REVIEW
Effie W Petersdorf
There are now more than 25 million volunteer donors registered worldwide for patients in need of a life-saving hematopoietic cell transplant to cure blood disorders. Although a human leukocyte antigen (HLA)-matched donor remains the preferred stem cell source for transplantation, the use of a donor with limited HLA mismatching may be considered. Significant advances in clinical and basic research have been instrumental in furthering the understanding of donor-recipient HLA mismatches that are better tolerated than other mismatches...
October 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27788759/matched-unrelated-donor-transplants-state-of-the-art-in-the-21st-century
#6
REVIEW
Syed Y Altaf, Jane F Apperley, Eduardo Olavarria
Hematopoietic stem cell transplantation (HSCT) is the therapy of choice in many hematological malignant and non-malignant diseases by using human leukocyte antigen (HLA)-matched siblings as stem cell source but only one third of the patients will have HLA-matched siblings. Hence, physicians rely on the availability of matched unrelated donors (URD). The possibility of finding a matched URD is now more than 70% due to continuous expansion of URD registries around the world. The use of URD in adult patients is steadily increasing and in the last 8 years has superseded the numbers of matched sibling donor transplants and has become the most commonly used stem cell source...
October 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27788758/alternative-donor-allogeneic-transplants-introduction
#7
EDITORIAL
Richard Childs, Didier Blaise
No abstract text is available yet for this article.
October 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27496314/similarity-of-fractionated-versus-single-dose-s-of-gemtuzumab-ozogamicin-as-part-of-the-midam-salvage-regimen-in-relapsed-refractory-acute-myeloid-leukemia-patients
#8
LETTER
Pierre Peterlin, Thierry Guillaume, Jacques Delaunay, Mohamad Mohty, Alice Garnier, Beatrice Mahe, Viviane Dubruille, Nicolas Blin, Maud Voldoire, Cyrille Touzeau, Cecile Chauvin, Thomas Gastinne, Marie C Béné, Steven Le Gouill, Philippe Moreau, Patrice Chevallier
No abstract text is available yet for this article.
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27496313/hodgkin-lymphoma-late-effects-of-treatment-and-guidelines-for-surveillance
#9
REVIEW
Andrea K Ng, Flora E van Leeuwen
Long-term survivors of Hodgkin lymphoma (HL) are at risk for a range of late effects, with second malignant neoplasm and cardiovascular diseases being the leading causes of death in these patients. The excess risks remain significantly elevated decades after treatment, and are clearly associated with extent of treatment exposures. Other late effects have also been identified, such as pulmonary dysfunction, endocrinopathies, muscle atrophy, and persistent fatigue. Systemic documentation of late effects and recognition of treatment- and patient-related risk factors are important, as they inform optimal surveillance and risk-reduction strategies, as well as guide therapeutic modifications in newly diagnosed patients to minimize treatment-related complications...
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27496312/hodgkin-lymphoma-in-the-elderly-pregnant-and-hiv-infected
#10
REVIEW
Veronika Bachanova, Joseph M Connors
Hodgkin lymphoma (HL) presenting in patients with co-incidental advanced age, pregnancy, or human immunodeficiency virus (HIV) infection is uniquely challenging to manage. In this article we integrate recent evidence and clinical expertise to present recommendations for diagnosis and therapeutic management. Older patients with HL need to be carefully evaluated for comorbidies after which judicious choice of chemotherapy should minimize functional compromise. A pregnant patient with concurrent HL should be staged with minimal use of imaging requiring ionizing radiation and treated in an individualized manner optimally combining the strategies of treatment deferral when appropriate, use of single-agent vinblastine for symptomatic disease and reservation of multi-agent chemotherapy for the small minority of patients with aggressive clinical presentation...
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27496311/nodular-lymphocyte-predominant-hodgkin-lymphoma
#11
REVIEW
Kerry J Savage, Anja Mottok, Michelle Fanale
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma with distinct clinicopathologic features. It is typified by the presence of lymphocyte predominant (LP) cells, which are CD20(+) but CD15(-) and CD30(-) and are found scattered amongst small B lymphocytes arranged in a nodular pattern. Despite frequent and often late or multiple relapses, the prognosis of NLPHL is very favorable. There is an inherent risk of secondary aggressive non-Hodgkin lymphoma (NHL) and studies support that risk is highest in those with splenic involvement at presentation...
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27496310/novel-agents-in-the-treatment-of-hodgkin-lymphoma-biological-basis-and-clinical-results
#12
REVIEW
Anas Younes, Stephen M Ansell
Hodgkin Lymphoma (HL) is a lymphoproliferative disorder of B cells that commonly has a favorable prognosis when treated with either combination chemotherapy and radiation therapy, or chemotherapy alone. However, the prognosis for patients who relapse, or have evidence for refractory disease, is poor and new treatments are needed for patients with progressive disease. HL has a unique tumor microenvironment consisting of a predominance of inflammatory cells and a minority of malignant Hodgkin and Reed-Sternberg (HRS) cells...
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27496309/treatment-of-relapsed-and-refractory-hodgkin-lymphoma
#13
REVIEW
Bastian von Tresckow, Craig H Moskowitz
Despite the high first-line cure rates in patients with Hodgkin Lymphoma (HL) still 10%-20% of patients suffer from relapsed or refractory disease. High-dose chemotherapy (HDCT) followed by autologous stem cell transplant (ASCT) is standard of care for suitable patients with relapsed or refractory HL and allows for cure in approximately 50%. Due to the poor prognosis of high-risk patients even with HDCT and ASCT, consolidation strategies have been evaluated to improve the cure rates. For patients with recurrence after HDCT and ASCT, treatment is palliative in most cases...
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27496308/treatment-of-advanced-stage-hodgkin-lymphoma
#14
REVIEW
Theodoros P Vassilakopoulos, Peter W M Johnson
There is now good evidence that the escalated BEACOPP regimen (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) is more effective in controlling advanced-stage Hodgkin lymphoma (HL) than the widely used ABVD regimen (adriamycin, bleomycin, vinblastine, dacarbazine), but the extra efficacy comes at the expense of both short- and long-term toxicity, and there is debate as to whether overall survival is affected. Baseline prognostic factors have proven of limited utility for determining which patients require more intensive therapy and recent studies have sought to use interim fluoro-deoxyglucose positron emission tomography (FDG-PET) evaluation as a means to guide the modulation of treatment, both upwards and downwards in intensity...
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27496307/treatment-of%C3%A2-early-stage-hodgkin-lymphoma
#15
REVIEW
Andreas Engert, John Raemaekers
Hodgkin lymphoma (HL) has become one of the best curable malignancies today. This is particularly true for patients with early-stage disease. Today, most patients in this risk group are treated with a combination of chemotherapy followed by small-field radiotherapy. More recent clinical trials such as the German Hodgkin Study Group (GHSG) HD10 study demonstrated, that even two cycles of ABVD followed by 20 Gy involved-field radiation therapy (IF-RT) are sufficient and result in more than 90% of patients being cured...
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27496306/prognostic-factors-in-hodgkin-lymphoma
#16
REVIEW
Paul J Bröckelmann, Maria K Angelopoulou, Theodoros P Vassilakopoulos
During the last decades, the prognosis of Hodgkin lymphoma (HL) has been improved significantly with the introduction of effective chemotherapy and the implementation of risk-adapted treatment approaches. Identification of reliable risk factors is crucial to guide treatment over the course of disease. Both clinical and biological factors have been implicated in the prognosis of HL and are often used in prognostic scores to discriminate risk groups. To prevent under- or overtreatment, patients are usually assigned to one of the three widely established risk groups for first-line treatment, based solely on clinical risk factors...
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27496305/clinical-presentation-and-staging-of-hodgkin-lymphoma
#17
REVIEW
Andrea Gallamini, Martin Hutchings, Safaa Ramadan
In the present chapter the authors present a brief overview of the diagnostic methods proposed over time for Hodgkin lymphoma (HL) spread detection, moving from surgical procedures, through standard radiological and functional imaging techniques to the present state of the art for HL staging. The main body of the review will be dedicated to the recently published guidelines for lymphoma staging (including HL) agreed by the experts during the 12th International Congress for Malignant Lymphoma in Lugano. The recommendations of the panel on how to integrate flurodeoxyglucose positron emission tomography (FDG-PET) scan in the armamentarium of staging procedures will be presented and commented, with a special emphasis on the utility of special procedures, such as bone marrow trephine biopsy, which is deemed no longer needed in the PET era...
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27496304/hodgkin-lymphoma-pathology-and-biology
#18
REVIEW
Stephan Mathas, Sylvia Hartmann, Ralf Küppers
The Hodgkin and Reed-Sternberg (HRS) tumor cells of classical Hodgkin lymphoma (HL), as well as the lymphocyte predominant (LP) cells of nodular lymphocyte predominant HL (NLPHL), are derived from mature B cells. However, HRS cells have largely lost their B-cell phenotype and show a very unusual expression of many markers of other hematopoietic cell lineages, which aids in the differential diagnosis between classical HL (cHL) and NLPHL and distinguishes cHL from all other hematopoietic malignancies. The bi- or multinucleated Reed-Sternberg cells most likely derive from the mononuclear Hodgkin cells through a process of incomplete cytokinesis...
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27496303/hodgkin-lymphoma-introduction
#19
EDITORIAL
Andreas Engert, Theodoros P Vassilakopoulos
No abstract text is available yet for this article.
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27312173/viruses-anti-viral-therapy-and-viral-vaccines-in-children-with-immune-thrombocytopenia
#20
Mohsen S Elalfy, Diane Nugent
Immune thrombocytopenia (ITP) might be preceded by silent or overt viral infections. Similarly, anti-viral drugs and viral vaccines could also trigger ITP and might play a central role in its pathogenesis. The seasonal nature of childhood ITP suggests that viral infections might initiate immune responses that increase the predisposition and occurrence of ITP. Active cytomegalovirus or Epstein-Barr virus should be considered in differential diagnosis when thrombocytopenia is associated with lymphadenopathy, especially with splenomegaly...
April 2016: Seminars in Hematology
journal
journal
24399
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"